GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 24, No. 10 ( 2006-04-01), p. 1507-1515
    Abstract: To determine whether minimal residual disease (MRD) measured by Wilms' tumor gene 1 (WT1) expression is a prognostic marker in pediatric acute myeloid leukemia (AML), we quantified WT1 transcript by real-time quantitative-polymerase chain reaction in 92 AML at diagnosis and during follow-up. Patients and Methods Patients (median age, 6 years; cytogenetics, favorable 27%, intermediate 59%, poor 13%) were treated between 1995 and 2002 and enrolled in Leucémie aiguë Myéloblastique Enfant (LAME) 89/91, LAME 99 pilot study and Acute Promyelocytic Leukemia French collaborative protocols. With a median follow-up of 26 months, event-free survival was 56% with a standard deviation (SD) of 5% and overall survival of 62.5% with an SD of 6%. WT1 copy number was normalized by TATA box binding protein gene transcripts and expressed as WT1/TBP × 1,000 ratio. Median WT1 ratio in normal patient controls was 12 (range, 0 to 57). A level over two SD than normal bone marrow controls (ie, WT1 ratio 〉 50), was considered as significant overexpression. Results At diagnosis, WT1 overexpression was detected in 78% of patients (72 of 92 patients; median copy ratio, 2231). The WT1 values were significantly higher (P = .01) in favorable cytogenetics and lower (P 〈 .0001) in M5-FAB subtype, 11q23 rearrangements (P 〈 .001), and infants (P = .003) and demonstrate a strong correlation with fusion transcript AML1-ETO, PML-RARα expression. After induction treatment, WT1 ratio was analyzed in 46 of 72 patients and found above 50 in nine of 36 patients and five of 25 patients at D35-50 and 3 to 5 months, respectively. WT1 ratio 〉 50 after induction is an independent prognostic risk factor of relapse (P = .002) and death (P = .02). Conclusion WT1 quantification is an informative molecular marker for MRD in pediatric AML and is now performed as prospective analysis in ELAM02 protocol.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2006
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 2998-2998
    Abstract: The Wilms’ s tumor gene (WT1) is a tumor suppressor gene highly expressed in most acute leukemias. To determine whether WT1 gene expression is a valuable and informative marker for minimal residual disease in pediatric AML, we quantified WT1 transcript amount by RQ-PCR in 92 de novo AML and 20 normal controls. The WT1 transcripts obtained were normalized with respect to the number of TBP transcripts and expressed as WT1 copy numbers by the ratio WT1/TBPx1000. The WT1 levels were extremely low in normal controls, and the median number of WT1 copies was 10 (range 4–30 ). A level above 50 copies was considered as significant. All the patients (aged 2 months-18 years, median age:5.9 years, male/female ratio 0.87) were treated for de novo AML between 1995 and 2003 in two French institutions and enrolled in LAM91, LAM01 and APLs French collaborative protocols. According to the FAB classification the repartition was: MO 5.4%, M1 4.3%, M2 18.5%, M3 14.1%, M4 and M4Eo 12%, M5 33.6 %, M7 10.9% and unclassified 1%. Cytogenetics features according to the MRC classification were favourable, intermediate or poor in 27% (23/83), 59% (49/83) and 13% (11/83) respectively. With a median follow up of 24 months (range 8–97months) OS was 75± 8% and EFS 60 ± 6%. At diagnosis WT1 overexpression was detected in 78.3% (72/92) with a median copy number of 2231 (range 50-429200). The WT1 values were significantly higher (p=0.02) in M2-FAB subtype and lower (p=0.01) in M5-FAB subtype while no correlation was found with WBC count or cytogenetic abnormalities. WT1 quantification for MRD was evaluable in 41/72 pts and positive in 9/32 at D40-50, 5/25 at M3-M5, 5/7at M6-M8. At least one analysis above 50 copies after induction therapy is associated with a significant risk of subsequent relapse 8/11 vs 8/30 ( p=0.007) RR=22 (IC 95%:46–118) and death 10/14 vs 3/30 (p=0.001) RR=7.3 (IC95%: 1–34). Although retrospective analysis may include bias, we conclude that WT1 is a useful and informative molecular marker for MRD in pediatric AML and performed as prospective analysis in ELAM02 protocol.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-01), p. 2283-2283
    Abstract: INTRODUCTION. Since the discovery of the cryptic t(12; 21) translocation, many secondary genetic abnormalities have been described in association with TEL-AML1 fusion gene. Extensive studies of karyotypes in a few series of TEL-AML1 positive leukaemia revealed a heterogeneous pattern of chromosomal abnormalities. Numerical and structural abnormalities are often present together. The modal chromosome number does not exceed 49 so that high hyperdiploidy and TEL-AML1 fusion are so far considered mutually exclusives. Here we reported that such association is found in a small group of patients and that relapse may still occur in those patients despite the good prognostic impact commonly attributed to each lesion. PATIENTS and METHODS. Between April 1994 and April 2006, 105 children were consecutively diagnosed with TEL-AML1 positive B-ALL. TEL-AML1 expression was detected by RT-PCR in Bone Marrow (BM) diagnostic samples and the t(12;21) explored by FISH with LSI TEL-AML1 dual-color probe (Vysis) in cases with low level of fusion gene expression or lacking molecular study. Conventional cytogenetics with G and R banding was performed on BM cells after overnight and 24 hours culture RESULTS and DISCUSSION. We detected numerical and/or structural abnormalities in 82/105 (78%) of the karyotypes. Aneuploidy alone was found in 4/105(3.8%): two cases had an extra chromosome 21, one an extra chromosome 10 and one lost 1 chromosome X. Structural abnormalities alone were present in 18/105 (17.1%) and up to 58 /105 (55.2%) presented both. The most frequent structural change was observed on chromosome 12p13 (50% of all structural abnormalities) whereas the most frequent chromosome gain was +21 (14%) and +10 (6.6%). Interestingly, in four cases (3.8%) we detected high hyperdiploidy with classical supplementary chromosomes; in two of these cases a partial trisomy of chromosome 1 was also present. Karyotypes are presented: Pt1: 52,XX,+10,+16,+18,+21,+21,+22 [22]/46, XX [4] Pt 2: 54,XY,+X,+4,+ 6?[del(6q)],+9,+14,+15,+18,+21,+21,-22 [17] /46,XY [3] Pt 3: 55,XX,+X,dup(1)(q21q31),+4,+6,+10,+14,+17,+18,+21,+21 [1]/56,idem+19 [4] /56,idem,+14 [5] / 46,XX [10] Pt 4: 7,XX,+der(X)(t(X;1)(q26;q12),+4,+5,+6,+8,+10,+14,+17,+18,+21,+21 [17]/46,XX [3] Pt1 present CNS relapse at 24 months follow up without involvement of BM which tested negative for TEL-AML1 expression. Patients 2,3,4 are in continuous complete remission at respectively 6, 6 and 4 years follow up. Since t(12;21) translocation and high hyperdiploidy seem to be primary events in leukaemia our observation raises the question if the two lesions coexist in a same cell or are independent events in different clones. In two cases (Pt 3,4), FISH analysis indicated the presence of TEL-AML1 gene fusion in 7% and in 5% of nuclei respectively. The distribution and the number of the signals on AML1 locus let think that t(12;21) occurred independently from hyperdiploidy. Microarrays studies have revealed distinct gene expression signatures associated to TEL-AML1 fusion and hyperdiploidy over 50 chromosomes, our observation points out the existence of cases which could be difficult to assign to one or the other of these classes.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 2015-2015
    Abstract: It is hypothesized that AML arises from two cooperative types of mutations: type I mutations mainly induce proliferation and type II mutations involved in the maturation arrest. AML is a rare disease in children and few molecular data are available on pediatric AML. We therefore studied N-RAS, K-RAS, FLT3-ITD, FLT3 , C-KIT mutations (type I), and CEBPA mutations (type II) as well as FLT3, EVI-1 and WT1 gene expression in 77 de novo AML. Patients and methods: All the patients (aged 1 month-17 years, median age: 6.9 years, male/female ratio 1.26) were treated for de novo AML between 1995 and 2003 in two French institutions and prospectively enrolled in LAM91, LAM01 and APLs French collaborative protocols. According to the FAB classification the repartition was: M0:6.5%, M1: 5.2%, M2: 22%, M3: 13%, M4 :14.3%, M5 :30%, M7: 6.5% and unclassified :2.5%. Cytogenetics features according to the MRC classification were favorable, intermediate or poor in 25% (t(8;21) n=5; t(15,17) n=8, inv(16) n=5), 65% (normal n=20 and 11q23 abnormalities n=15) and 10% (−7, n=4) respectively. With a median follow-up of 26 months (range 2–98 months), Complete Remission was obtained in 92% (71/77) of patients, OS was 71% and EFS 61%. CEBPA, N-RAS, K-RAS, C-KIT and FLT3 mutations detection was performed by direct sequencing. FLT3, EVI-1 and WT1 transcripts were quantified by RQ-PCR. Results: (1) Frequency of N-RAS and K-RAS mutations were 11% (8/75) and 16% (12/75) respectively. RAS-mutated patients belonged to favorable (30%), intermediate (60%) and poor (10%) cytogenetic subgroups. In univariate analysis only N-RAS mutations is associated with adverse outcome (OS 37% vs 79%, p 〈 0.05). (2) CEBPA mutations were found in 8% (6/75), mostly belonged to the intermediate cytogenetic risk subgroup (66%). (3) C-KIT mutations were observed in 4% (4/75) always associated with fusion CBFb/MYH11 transcript and excellent outcome. (4) FLT3-ITD and FLT3 Asp835 mutations were obtained in 12% (9/74) and 4% (3/74) of patients respectively. Cytogenetic subgroups were favorable (33%) and intermediate (67%). (5) At diagnosis FLT3 overexpression was detected in 34% (24/70) and 11q23 abnormalities were associated in 7/24 patients. (6) EVI-1 overexpression was found in 21% (16/76), belonged to intermediate (85%) and poor (15%) cytogenetic subgroups with a significant frequency in monosomy 7 (p 〈 0.025). The EVI-1 expression was specifically expressed (p 〈 0.001) in M5 and M7-FAB subtypes. (7) WT1 overexpression was detected in 81% (62/76). Conclusion: In total, 48% of de novo AML in children had a mutation in N-RAS, K-RAS, FLT3-ITD, FLT3 Asp835, C-KIT or CEBPA with a high frequency of RAS mutations (27%) compared to adult AML and a significantly bad survival. Additional gene expression quantification of EVI-1, FLT3 and WT1 allows MDR detection in 95% of patients.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...